Citalopram

Citalopram is used to treat depression. Citalopram is in a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It works by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance.

Citalopram comes as a tablet and a solution (liquid) to take by mouth. It is usually taken once a day, in the morning or in the evening, with or without food. Take citalopram at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take citalopram exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor may start you on a low dose of citalopram and gradually increase your dose, not more often than once a week.

It may take 1 to 4 weeks before you notice the full benefit of citalopram. Continue to take citalopram even if you feel well. Do not stop taking citalopram without talking to your doctor. Your doctor will probably decrease your dose gradually. If you suddenly stop taking citalopram, you may experience withdrawal symptoms such as mood changes, irritability, agitation, dizziness, numbness, tingling or electric shock-like sensations in the hands or feet, anxiety, confusion, headache, tiredness, nausea, sweating, shaking, frenzied or abnormally excited mood, and difficulty falling asleep or staying asleep. Tell your doctor if you experience any of these symptoms while you are decreasing your dose of citalopram or soon after you stop taking citalopram.

Citalopram is also sometimes used to treat obsessive-compulsive disorder (bothersome thoughts that won't go away and the need to perform certain actions over and over), eating disorders, alcoholism, panic disorder (condition that causes sudden attacks of extreme fear with no apparent cause), premenstrual dysphoric disorder (a group of physical and emotional symptoms that occur before the menstrual period each month), social anxiety disorder (extreme fear of interacting with others or performing in front of others that interferes with normal life), posttraumatic stress disorder, tingling in the hands and feet caused by diabetes, and certain male sexual problems. Talk to your doctor about the possible risks of using this medication for your condition.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking citalopram,

• tell your doctor and pharmacist if you are allergic to citalopram, escitalopram (Lexapro), any other medications, or any of the ingredients in the citalopram product you are taking. Talk to your pharmacist or check the Medication Guide for a list of the ingredients.

• tell your doctor if you are taking pimozide (Orap) or a monoamine oxidase (MAO) inhibitor such as isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), selegiline (Emsam, Zelapar), or tranylcypromine (Parnate), or if you have stopped taking an MAO inhibitor within the past 14 days. Your doctor will probably tell you not to take citalopram. If you stop taking citalopram, you should wait at least 14 days before you start to take an MAO inhibitor.

• you should know that citalopram is very similar to another SSRI, escitalopram (Lexapro). You should not take these two medications together.

• tell your doctor and pharmacist what other prescription and nonprescription medications and vitamins you are taking or plan to take. Be sure to mention any of the following: amiodarone (Nexterone, Pacerone); amphetamines such as amphetamine (in Adderall, in Mydayis), dextroamphetamine (Dexedrine, in Adderall), and methamphetamine (Desoxyn); anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin) and naproxen (Aleve, Naprosyn); carbamazepine (Carbatrol, Equetro, Tegretol, others); chlorpromazine; cimetidine (Tagamet); diuretics ('water pills); disopyramide (Norpace); dofetilide (Tikosyn); erythromycin (E.E.S. Ery-Tab, Erythrocin); fentanyl (Actiq, Duragesic, Fentora, Subsys); lithium (Lithobid); medications for anxiety, chronic pain, mental illness, and seizures; medications for migraine headaches such as almotriptan, eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex, Tosymra, in Treximet), and zolmitriptan (Zomig); methadone (Methadose); metoprolol (Lopressor, Toprol XL); moxifloxacin; omeprazole (Prilosec, Zegerid); pentamidine (Nebupent, Pentam); other SSRIs such as fluoxetine (Prozac, in Symbyax), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft); serotonin–norepinephrine reuptake inhibitors (SNRIs) such as duloxetine (Cymbalta); procainamide; quinidine (in Nuedexta); sedatives; sleeping pills; sotalol (Betapace, Sorine, Sotylize); thioridazine (Mellaril); tramadol (Conzip, Qdolo, Ultram, in Ultracet); tranquilizers; and tricyclic antidepressants such as amitriptyline, amoxapine, clomipramine (Anafranil), desipramine (Norpramin), doxepin (Silenor), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline, and trimipramine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with citalopram, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

• tell your doctor what nutritional supplements and herbal products you are taking, especially products that contain St. John's wort or tryptophan.

• tell your doctor if you drink or have ever drunk large amounts of alcohol or use or have ever used street drugs or have ever overused prescription medications. Also tell your doctor if you or anyone in your family has or has ever had long QT syndrome (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death),if you have recently had a heart attack, or if you have or have ever had a slow or irregular heartbeat, heart failure (condition in which the heart cannot pump enough blood to other parts of the body) or other heart conditions; high blood pressure; bleeding problems; stroke; low levels of magnesium, potassium, or sodium in your blood; seizures; or kidney or liver disease.

• tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breast-feeding. If you become pregnant while taking citalopram, call your doctor. Citalopram may cause problems in newborns following delivery if it is taken during the last months of pregnancy.

• you should know that citalopram may make you drowsy and may affect your judgment, thinking, and movements. Do not drive a car or operate machinery until you know how this medication affects you.

• talk to your doctor about the safe use of alcoholic beverages during your treatment with citalopram. Alcohol can make the side effects of citalopram worse.

• you should know that citalopram may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Talk to your doctor about having an eye examination before you start taking this medication. If you have nausea, eye pain, changes in vision, such as seeing colored rings around lights, and swelling or redness in or around the eye, call your doctor or get emergency medical treatment right away.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

• Citalopram may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • nausea

  • diarrhea

  • constipation

  • vomiting

  • stomach pain

  • heartburn

  • decreased appetite

  • weight loss

  • increased sweating

  • increased thirst

  • frequent urination

  • difficulty falling asleep or staying asleep

  • drowsiness

  • excessive tiredness

  • yawning

  • weakness

  • uncontrollable shaking of a part of the body

  • muscle or joint pain

  • dry mouth

  • sexual problems in males; decreased sex drive, inability to get or keep an erection, or delayed or absent ejaculation

  • sexual problems in females; decreased sex drive, or delayed orgasm or inability to have an orgasm

  • heavy menstrual periods

  • runny nose

• Some side effects can be serious. If you experience any of the following symptoms, or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS sections, call your doctor immediately or get emergency medical treatment:

  • chest pain

  • shortness of breath

  • dizziness

  • fainting

  • fever, sweating, confusion, fast or irregular heartbeat, severe muscle stiffness or twitching, agitation, hallucinations, loss of coordination, nausea, vomiting, or diarrhea

  • coma (loss of consciousness)

  • hives or blisters

  • rash

  • itching

  • difficulty breathing or swallowing

  • swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs

  • hoarseness

  • unusual bleeding or bruising

  • nose bleeding

  • headache

  • unsteadiness

  • problems with thinking, concentration, or memory

  • seizures

• Citalopram may decrease appetite and cause weight loss in children. Your child's doctor will watch his or her growth carefully. Talk to your child's doctor if you have concerns about your child's growth or weight while he or she is taking this medication. Talk to your child's doctor about the risks of giving citalopram to your child.

• Citalopram may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

• If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

• dizziness

• sweating

• nausea

• vomiting

• uncontrollable shaking of a part of the body

• drowsiness

• fast, irregular, or pounding heartbeat

• memory loss

• confusion

• seizures

• coma (loss of consciousness)

• fast breathing

• bluish color around mouth, fingers, or fingernails

• muscle pain

• dark-colored urine

Keep all appointments with your doctor and the laboratory. Your doctor may order certain laboratory tests and electrocardiograms (EKG; a test to monitor your heart rate and rhythm) before you start taking citalopram and during your treatment with this medication.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug	Interaction
Moxifloxacin	Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Citalopram.
Repaglinide	Repaglinide The risk or severity of hypoglycemia can be increased when Citalopram is combined with Repaglinide.
Insulin Glargine (rDNA origin) Injection	Insulin Glargine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Citalopram.
Leflunomide	Leflunomide The metabolism of Leflunomide can be decreased when combined with Citalopram.
Delavirdine	Delavirdine The serum concentration of Citalopram can be increased when it is combined with Delavirdine.
Nevirapine	Nevirapine The metabolism of Nevirapine can be decreased when combined with Citalopram.
Atorvastatin	Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Citalopram.
Dolasetron	Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Citalopram.
Aminophylline	Aminophylline The metabolism of Aminophylline can be decreased when combined with Citalopram.
Anagrelide	Anagrelide The risk or severity of QTc prolongation can be increased when Citalopram is combined with Anagrelide.
Cilostazol	Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Citalopram.
Clopidogrel	Clopidogrel The risk or severity of hemorrhage can be increased when Citalopram is combined with Clopidogrel.
Diphenoxylate	Diphenoxylate The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Citalopram.
Erythromycin and Sulfisoxazole	Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Citalopram.
Estrogen and Progestin (Oral Contraceptives)	Estrogen and Progestin (Oral Contraceptives) The metabolism of Conjugated estrogens can be decreased when combined with Citalopram.
Fenofibrate	Fenofibrate The risk or severity of QTc prolongation can be increased when Fenofibrate is combined with Citalopram.
Guanfacine	Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Citalopram.
Miglitol	Miglitol The risk or severity of hypoglycemia can be increased when Citalopram is combined with Miglitol.
Naratriptan	Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Citalopram.
Olsalazine	Olsalazine The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Olsalazine.
Paregoric	Paregoric The risk or severity of serotonin syndrome can be increased when Morphine is combined with Citalopram.
Penbutolol	Penbutolol The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Citalopram.
Pentazocine	Pentazocine The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Citalopram.
Ranitidine	Ranitidine The metabolism of Ranitidine can be decreased when combined with Citalopram.
Reserpine	Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Citalopram.
Rizatriptan	Rizatriptan The risk or severity of adverse effects can be increased when Citalopram is combined with Rizatriptan.
Sumatriptan	Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Citalopram.
Tacrolimus	Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Citalopram.
Tizanidine	Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Citalopram.
Zolmitriptan	Zolmitriptan The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Zolmitriptan.
Famotidine Injection	Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Citalopram.
Fluconazole Injection	Fluconazole Injection The risk or severity of QTc prolongation and serotonin syndrome can be increased when Fluconazole is combined with Citalopram.
Foscarnet Injection	Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Citalopram.
Hydromorphone Injection	Hydromorphone Injection The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Citalopram.
Levofloxacin Injection	Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Citalopram.
Meperidine Injection	Meperidine Injection The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Meperidine.
Metoclopramide Injection	Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Citalopram.
Metronidazole Injection	Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Citalopram.
Morphine Injection	Morphine Injection The risk or severity of serotonin syndrome can be increased when Morphine is combined with Citalopram.
Altretamine	Altretamine The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Citalopram.
Cyclosporine	Cyclosporine The metabolism of Citalopram can be decreased when combined with Cyclosporine.
Ondansetron	Ondansetron The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ondansetron.
Enoxaparin Injection	Enoxaparin Injection The risk or severity of hemorrhage can be increased when Citalopram is combined with Enoxaparin.
Granisetron	Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Citalopram.
Olanzapine	Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Citalopram.
Alosetron	Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Citalopram.
Dofetilide	Dofetilide The metabolism of Citalopram can be decreased when combined with Dofetilide.
Entacapone	Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Citalopram.
Hydroxychloroquine	Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Citalopram.
Meloxicam	Meloxicam The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Meloxicam.
Oxcarbazepine	Oxcarbazepine Oxcarbazepine may increase the QTc-prolonging activities of Citalopram.
Pantoprazole	Pantoprazole The risk or severity of QTc prolongation can be increased when Pantoprazole is combined with Citalopram.
Telmisartan	Telmisartan Telmisartan may increase the QTc-prolonging activities of Citalopram.
Zaleplon	Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram.
Anakinra	Anakinra The metabolism of Citalopram can be increased when combined with Anakinra.
Desloratadine	Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Citalopram.
Linezolid	Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Citalopram.
Pentosan Polysulfate	Pentosan Polysulfate The risk or severity of hemorrhage can be increased when Citalopram is combined with Pentosan polysulfate.
Trimipramine	Trimipramine The metabolism of Citalopram can be decreased when combined with Trimipramine.
Etanercept Injection	Etanercept Injection The metabolism of Citalopram can be increased when combined with Etanercept.
Glycopyrrolate	Glycopyrrolate Citalopram may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil	Modafinil The serum concentration of Citalopram can be increased when it is combined with Armodafinil.
Tenofovir	Tenofovir The metabolism of Tenofovir can be decreased when combined with Citalopram.
Choline Magnesium Trisalicylate	Choline Magnesium Trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Choline magnesium trisalicylate.
Sirolimus	Sirolimus The metabolism of Sirolimus can be decreased when combined with Citalopram.
Escitalopram	Escitalopram The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Escitalopram.
Zonisamide	Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Citalopram.
Adalimumab Injection	Adalimumab Injection The metabolism of Citalopram can be increased when combined with Adalimumab.
Aripiprazole	Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Citalopram.
Atomoxetine	Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Citalopram.
Dexmethylphenidate	Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Citalopram.
Teriparatide Injection	Teriparatide Injection The therapeutic efficacy of Teriparatide can be decreased when used in combination with Citalopram.
Atazanavir	Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Citalopram.
Almotriptan	Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Citalopram.
Eletriptan	Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Citalopram.
Mefloquine	Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Citalopram.
Rosuvastatin	Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Citalopram.
Vardenafil	Vardenafil The metabolism of Vardenafil can be decreased when combined with Citalopram.
Alfuzosin	Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Citalopram.
Aprepitant	Aprepitant Aprepitant may increase the QTc-prolonging activities of Citalopram.
Memantine	Memantine The risk or severity of QTc prolongation can be increased when Memantine is combined with Citalopram.
Tegaserod	Tegaserod The metabolism of Tegaserod can be decreased when combined with Citalopram.
Frovatriptan	Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Citalopram.
Gemifloxacin	Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Citalopram.
Progesterone	Progesterone Progesterone may increase the QTc-prolonging activities of Citalopram.
Apomorphine Injection	Apomorphine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Citalopram.
Infliximab Injection	Infliximab Injection The metabolism of Citalopram can be increased when combined with Infliximab.
Protriptyline	Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram.
Rifaximin	Rifaximin The metabolism of Citalopram can be increased when combined with Rifaximin.
Duloxetine	Duloxetine The metabolism of Duloxetine can be decreased when combined with Citalopram.
Norethindrone	Norethindrone The metabolism of Norethisterone can be decreased when combined with Citalopram.
Trospium	Trospium Citalopram may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Cinacalcet	Cinacalcet The metabolism of Citalopram can be decreased when combined with Cinacalcet.
Erlotinib	Erlotinib The metabolism of Erlotinib can be decreased when combined with Citalopram.
Eszopiclone	Eszopiclone The risk or severity of CNS depression can be increased when Citalopram is combined with Eszopiclone.
Insulin Aspart (rDNA Origin) Injection	Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin aspart.
Solifenacin	Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Citalopram.
Voriconazole	Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Citalopram.
Dextroamphetamine	Dextroamphetamine The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Citalopram.
Entecavir	Entecavir The metabolism of Entecavir can be decreased when combined with Citalopram.
Peginterferon Alfa-2b (PEG-Intron)	Peginterferon Alfa-2b (PEG-Intron) The metabolism of Citalopram can be decreased when combined with Peginterferon alfa-2b.
Pramlintide Injection	Pramlintide Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Pramlintide.
Sodium Oxybate	Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Citalopram.
Exenatide Injection	Exenatide Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Exenatide.
Ibandronate	Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Citalopram.
Isocarboxazid	Isocarboxazid The risk or severity of serotonin syndrome can be increased when Isocarboxazid is combined with Citalopram.
Ramelteon	Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Citalopram.
Darifenacin	Darifenacin The metabolism of Darifenacin can be decreased when combined with Citalopram.
Fentanyl	Fentanyl The metabolism of Fentanyl can be decreased when combined with Citalopram.
Pregabalin	Pregabalin The therapeutic efficacy of Citalopram can be increased when used in combination with Pregabalin.
Tipranavir	Tipranavir The risk or severity of QTc prolongation can be increased when Tipranavir is combined with Citalopram.
Felbamate	Felbamate Felbamate may increase the QTc-prolonging activities of Citalopram.
Insulin Detemir (rDNA Origin) Injection	Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin detemir.
Ranolazine	Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Citalopram.
Abatacept Injection	Abatacept Injection The metabolism of Citalopram can be increased when combined with Abatacept.
Rasagiline	Rasagiline The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Citalopram.
Imatinib	Imatinib The risk or severity of QTc prolongation can be increased when Citalopram is combined with Imatinib.
Sitagliptin	Sitagliptin The risk or severity of hypoglycemia can be increased when Citalopram is combined with Sitagliptin.
Gefitinib	Gefitinib Gefitinib may increase the QTc-prolonging activities of Citalopram.
Albuterol	Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Citalopram.
Paliperidone	Paliperidone The risk or severity of QTc prolongation can be increased when Citalopram is combined with Paliperidone.
Bortezomib	Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Citalopram.
Insulin Glulisine (rDNA origin) Injection	Insulin Glulisine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin glulisine.
Oxaliplatin Injection	Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Citalopram.
Posaconazole	Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Citalopram.
Primaquine	Primaquine The metabolism of Citalopram can be decreased when combined with Primaquine.
Pemetrexed Injection	Pemetrexed Injection The metabolism of Pemetrexed can be decreased when combined with Citalopram.
Dimenhydrinate	Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Citalopram.
Lisdexamfetamine	Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Lisdexamfetamine.
Nabilone	Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Citalopram.
Retapamulin	Retapamulin The metabolism of Retapamulin can be decreased when combined with Citalopram.
Vorinostat	Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Citalopram.
Sorafenib	Sorafenib Sorafenib may increase the QTc-prolonging activities of Citalopram.
Sunitinib	Sunitinib The metabolism of Citalopram can be decreased when combined with Sunitinib.
Dronabinol	Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Citalopram.
Lapatinib	Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Citalopram.
Levocetirizine	Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Citalopram.
Dasatinib	Dasatinib The metabolism of Dasatinib can be decreased when combined with Citalopram.
Mexiletine	Mexiletine The metabolism of Mexiletine can be decreased when combined with Citalopram.
Armodafinil	Armodafinil The serum concentration of Citalopram can be increased when it is combined with Armodafinil.
Temsirolimus	Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Citalopram.
Nilotinib	Nilotinib The metabolism of Nilotinib can be decreased when combined with Citalopram.
Toremifene	Toremifene The risk or severity of QTc prolongation can be increased when Citalopram is combined with Toremifene.
Chloramphenicol Injection	Chloramphenicol Injection The serum concentration of Citalopram can be increased when it is combined with Chloramphenicol.
Desmopressin	Desmopressin The risk or severity of hyponatremia can be increased when Citalopram is combined with Desmopressin.
OnabotulinumtoxinA Injection	OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Citalopram.
RimabotulinumtoxinB Injection	RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Citalopram.
Etravirine	Etravirine Etravirine may increase the QTc-prolonging activities of Citalopram.
Arsenic Trioxide Injection	Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Citalopram is combined with Arsenic trioxide.
Desvenlafaxine	Desvenlafaxine The risk or severity of adverse effects can be increased when Citalopram is combined with Desvenlafaxine.
Cevimeline	Cevimeline The metabolism of Cevimeline can be decreased when combined with Citalopram.
Nebivolol	Nebivolol The metabolism of Nebivolol can be decreased when combined with Citalopram.
Bendamustine Injection	Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Citalopram.
Flecainide	Flecainide The metabolism of Flecainide can be decreased when combined with Citalopram.
Certolizumab Injection	Certolizumab Injection The metabolism of Citalopram can be increased when combined with Certolizumab pegol.
Ixabepilone Injection	Ixabepilone Injection The metabolism of Ixabepilone can be decreased when combined with Citalopram.
Irinotecan Injection	Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Citalopram.
Praziquantel	Praziquantel The metabolism of Praziquantel can be decreased when combined with Citalopram.
Rufinamide	Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Citalopram.
Midazolam	Midazolam The serum concentration of Midazolam can be increased when it is combined with Citalopram.
Naltrexone Injection	Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Naltrexone.
Eltrombopag	Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Citalopram.
Milnacipran	Milnacipran The risk or severity of adverse effects can be increased when Citalopram is combined with Milnacipran.
Dexlansoprazole	Dexlansoprazole The risk or severity of QTc prolongation can be increased when Dexlansoprazole is combined with Citalopram.
Fesoterodine	Fesoterodine Citalopram may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection	Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Citalopram.
Betaxolol	Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Citalopram.
Iloperidone	Iloperidone The metabolism of Iloperidone can be decreased when combined with Citalopram.
Prasugrel	Prasugrel The risk or severity of hemorrhage can be increased when Citalopram is combined with Prasugrel.
Lacosamide	Lacosamide The risk or severity of adverse effects can be increased when Lacosamide is combined with Citalopram.
Everolimus	Everolimus The metabolism of Everolimus can be decreased when combined with Citalopram.
Tolvaptan (low blood sodium)	Tolvaptan (low blood sodium) The metabolism of Tolvaptan can be decreased when combined with Citalopram.
Dronedarone	Dronedarone Citalopram may increase the QTc-prolonging activities of Dronedarone.
AbobotulinumtoxinA Injection	AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Citalopram.
Palonosetron Injection	Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Citalopram.
Saxagliptin	Saxagliptin The risk or severity of hypoglycemia can be increased when Citalopram is combined with Saxagliptin.
Telavancin Injection	Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Citalopram.
Romidepsin Injection	Romidepsin Injection The metabolism of Romidepsin can be decreased when combined with Citalopram.
Tapentadol	Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Citalopram.
Golimumab Injection	Golimumab Injection The metabolism of Citalopram can be increased when combined with Golimumab.
Pazopanib	Pazopanib The metabolism of Pazopanib can be decreased when combined with Citalopram.
Asenapine	Asenapine The risk or severity of QTc prolongation can be increased when Citalopram is combined with Asenapine.
Vigabatrin	Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Citalopram.
Albendazole	Albendazole The metabolism of Albendazole can be decreased when combined with Citalopram.
Oxymorphone	Oxymorphone The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Citalopram.
Dabigatran	Dabigatran The risk or severity of hemorrhage can be increased when Citalopram is combined with Dabigatran.
Liraglutide Injection	Liraglutide Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Liraglutide.
Tocilizumab Injection	Tocilizumab Injection The metabolism of Citalopram can be increased when combined with Tocilizumab.
Eribulin Injection	Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Citalopram.
IncobotulinumtoxinA Injection	IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Citalopram.
Cabazitaxel Injection	Cabazitaxel Injection The metabolism of Cabazitaxel can be decreased when combined with Citalopram.
Lurasidone	Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Citalopram.
Acetaminophen Injection	Acetaminophen Injection The metabolism of Acetaminophen can be decreased when combined with Citalopram.
Vilazodone	Vilazodone The metabolism of Vilazodone can be decreased when combined with Citalopram.
Terbutaline Injection	Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Citalopram.
Busulfan Injection	Busulfan Injection The metabolism of Busulfan can be decreased when combined with Citalopram.
Roflumilast	Roflumilast The metabolism of Roflumilast can be decreased when combined with Citalopram.
Linagliptin	Linagliptin The risk or severity of hypoglycemia can be increased when Citalopram is combined with Linagliptin.
Rilpivirine	Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Citalopram.
Potassium Iodide	Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Citalopram.
Cyclophosphamide Injection	Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Citalopram.
Abiraterone	Abiraterone The serum concentration of Citalopram can be increased when it is combined with Abiraterone.
Triptorelin Injection	Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Citalopram.
Rivaroxaban	Rivaroxaban The risk or severity of hemorrhage can be increased when Citalopram is combined with Rivaroxaban.
Ticagrelor	Ticagrelor The risk or severity of hemorrhage can be increased when Citalopram is combined with Ticagrelor.
Brentuximab Vedotin Injection	Brentuximab Vedotin Injection The metabolism of Brentuximab vedotin can be decreased when combined with Citalopram.
Ruxolitinib	Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Citalopram.
Vandetanib	Vandetanib The metabolism of Vandetanib can be decreased when combined with Citalopram.
Clobazam	Clobazam The metabolism of Clobazam can be decreased when combined with Citalopram.
Vemurafenib	Vemurafenib The metabolism of Citalopram can be decreased when combined with Vemurafenib.
Vismodegib	Vismodegib Vismodegib may increase the QTc-prolonging activities of Citalopram.
Axitinib	Axitinib The metabolism of Axitinib can be decreased when combined with Citalopram.
Crizotinib	Crizotinib The metabolism of Citalopram can be decreased when combined with Crizotinib.
Cabergoline	Cabergoline The metabolism of Cabergoline can be decreased when combined with Citalopram.
Fondaparinux Injection	Fondaparinux Injection The risk or severity of hemorrhage can be increased when Citalopram is combined with Fondaparinux.
Ezogabine	Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Citalopram.
Iloprost	Iloprost The risk or severity of hemorrhage can be increased when Citalopram is combined with Iloprost.
Enzalutamide	Enzalutamide The metabolism of Citalopram can be increased when combined with Enzalutamide.
Mirabegron	Mirabegron The metabolism of Citalopram can be decreased when combined with Mirabegron.
Regorafenib	Regorafenib The metabolism of Regorafenib can be decreased when combined with Citalopram.
Bosutinib	Bosutinib The metabolism of Bosutinib can be decreased when combined with Citalopram.
Lorcaserin	Lorcaserin The risk or severity of hypoglycemia can be increased when Citalopram is combined with Mecasermin.
Bedaquiline	Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Citalopram.
Icosapent Ethyl	Icosapent Ethyl The risk or severity of hemorrhage can be increased when Citalopram is combined with Icosapent ethyl.
Tofacitinib	Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Citalopram.
Alogliptin	Alogliptin The metabolism of Alogliptin can be decreased when combined with Citalopram.
Ponatinib	Ponatinib The metabolism of Ponatinib can be decreased when combined with Citalopram.
Pomalidomide	Pomalidomide The metabolism of Citalopram can be decreased when combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection	Ado-trastuzumab Emtansine Injection The metabolism of Trastuzumab emtansine can be decreased when combined with Citalopram.
Apixaban	Apixaban The risk or severity of hemorrhage can be increased when Citalopram is combined with Apixaban.
Canagliflozin	Canagliflozin The risk or severity of hypoglycemia can be increased when Citalopram is combined with Canagliflozin.
Dabrafenib	Dabrafenib The serum concentration of Citalopram can be decreased when it is combined with Dabrafenib.
Ospemifene	Ospemifene The metabolism of Citalopram can be decreased when combined with Ospemifene.
Levomilnacipran	Levomilnacipran The risk or severity of adverse effects can be increased when Citalopram is combined with Levomilnacipran.
Vortioxetine	Vortioxetine The risk or severity of adverse effects can be increased when Citalopram is combined with Vortioxetine.
Perampanel	Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Citalopram.
Ibrutinib	Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Citalopram.
Lomitapide	Lomitapide The metabolism of Lomitapide can be decreased when combined with Citalopram.
Ketorolac Injection	Ketorolac Injection The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ketorolac.
Dapagliflozin	Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Citalopram.
Apremilast	Apremilast The metabolism of Citalopram can be increased when combined with Apremilast.
Ceritinib	Ceritinib The metabolism of Citalopram can be decreased when combined with Ceritinib.
Siltuximab Injection	Siltuximab Injection The metabolism of Citalopram can be increased when combined with Siltuximab.
Albiglutide Injection	Albiglutide Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Albiglutide.
Eslicarbazepine	Eslicarbazepine Eslicarbazepine may increase the QTc-prolonging activities of Citalopram.
Idelalisib	Idelalisib The metabolism of Idelalisib can be decreased when combined with Citalopram.
Testosterone Injection	Testosterone Injection The metabolism of Testosterone can be decreased when combined with Citalopram.
Oritavancin Injection	Oritavancin Injection The risk or severity of QTc prolongation can be increased when Oritavancin is combined with Citalopram.
Empagliflozin	Empagliflozin The risk or severity of hypoglycemia can be increased when Citalopram is combined with Empagliflozin.
Vorapaxar	Vorapaxar The risk or severity of hemorrhage can be increased when Citalopram is combined with Vorapaxar.
Hydrocodone	Hydrocodone Citalopram may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant	Suvorexant Citalopram may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection	Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Dulaglutide.
Edoxaban	Edoxaban The risk or severity of hemorrhage can be increased when Citalopram is combined with Edoxaban.
Olaparib	Olaparib The metabolism of Olaparib can be decreased when combined with Citalopram.
Methamphetamine	Methamphetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Citalopram.
Tasimelteon	Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Citalopram.
Lanreotide Injection	Lanreotide Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Lanreotide.
Pirfenidone	Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Citalopram.
Nintedanib	Nintedanib The metabolism of Nintedanib can be decreased when combined with Citalopram.
Secukinumab Injection	Secukinumab Injection The metabolism of Citalopram can be increased when combined with Secukinumab.
Risperidone Injection	Risperidone Injection The risk or severity of adverse effects can be increased when Citalopram is combined with Risperidone.
Palbociclib	Palbociclib The metabolism of Palbociclib can be decreased when combined with Citalopram.
Insulin Human Inhalation	Insulin Human Inhalation The risk or severity of hypoglycemia can be increased when Insulin human is combined with Citalopram.
Lenvatinib	Lenvatinib Lenvatinib may increase the QTc-prolonging activities of Citalopram.
Naloxegol	Naloxegol The risk or severity of QTc prolongation can be increased when Citalopram is combined with Naloxegol.
Panobinostat	Panobinostat The metabolism of Citalopram can be decreased when combined with Panobinostat.
Haloperidol Injection	Haloperidol Injection The risk or severity of QTc prolongation can be increased when Citalopram is combined with Haloperidol.
Ivabradine	Ivabradine The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ivabradine.
Sonidegib	Sonidegib The metabolism of Sonidegib can be decreased when combined with Citalopram.
Flibanserin	Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Citalopram.
Rolapitant	Rolapitant The metabolism of Citalopram can be decreased when combined with Rolapitant.
Brexpiprazole	Brexpiprazole The risk or severity of adverse effects can be increased when Citalopram is combined with Brexpiprazole.
Ziprasidone Injection	Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ziprasidone.
Cariprazine	Cariprazine The risk or severity of adverse effects can be increased when Citalopram is combined with Cariprazine.
Eluxadoline	Eluxadoline The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection	Insulin Degludec (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin degludec.
Cobimetinib	Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Citalopram.
Trabectedin Injection	Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Citalopram.
Osimertinib	Osimertinib The metabolism of Osimertinib can be decreased when combined with Citalopram.
Alectinib	Alectinib The metabolism of Alectinib can be decreased when combined with Citalopram.
Ixazomib	Ixazomib The metabolism of Ixazomib can be decreased when combined with Citalopram.
Rifapentine	Rifapentine The metabolism of Citalopram can be increased when combined with Rifapentine.
Defibrotide Injection	Defibrotide Injection The risk or severity of hemorrhage can be increased when Citalopram is combined with Defibrotide.
Brivaracetam Injection	Brivaracetam Injection The risk or severity of adverse effects can be increased when Brivaracetam is combined with Citalopram.
Venetoclax	Venetoclax The metabolism of Venetoclax can be decreased when combined with Citalopram.
Cobicistat	Cobicistat The metabolism of Citalopram can be decreased when combined with Cobicistat.
Pimavanserin	Pimavanserin The risk or severity of adverse effects can be increased when Citalopram is combined with Pimavanserin.
Diphenhydramine Injection	Diphenhydramine Injection The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Citalopram.
Rucaparib	Rucaparib The risk or severity of QTc prolongation can be increased when Rucaparib is combined with Citalopram.
Lixisenatide Injection	Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Lixisenatide.
Ribociclib	Ribociclib The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ribociclib.
Parathyroid Hormone Injection	Parathyroid Hormone Injection The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Citalopram.
Brigatinib	Brigatinib The metabolism of Brigatinib can be decreased when combined with Citalopram.
Doxepin (Insomnia)	Doxepin (Insomnia) The risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.
Deutetrabenazine	Deutetrabenazine The risk or severity of QTc prolongation can be increased when Citalopram is combined with Deutetrabenazine.
Valbenazine	Valbenazine The metabolism of Valbenazine can be decreased when combined with Citalopram.
Safinamide	Safinamide The risk or severity of serotonin syndrome can be increased when Safinamide is combined with Citalopram.
Midostaurin	Midostaurin The risk or severity of QTc prolongation can be increased when Midostaurin is combined with Citalopram.
Neratinib	Neratinib The metabolism of Neratinib can be decreased when combined with Citalopram.
Abaloparatide Injection	Abaloparatide Injection The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Citalopram.
Enasidenib	Enasidenib Enasidenib may increase the QTc-prolonging activities of Citalopram.
Aprepitant/Fosaprepitant Injection	Aprepitant/Fosaprepitant Injection The metabolism of Fosaprepitant can be decreased when combined with Citalopram.
Copanlisib Injection	Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Citalopram.
Delafloxacin	Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Citalopram.
Abemaciclib	Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Citalopram.
Betrixaban	Betrixaban The risk or severity of hemorrhage can be increased when Citalopram is combined with Betrixaban.
Acalabrutinib	Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Citalopram.
Letermovir	Letermovir The metabolism of Letermovir can be decreased when combined with Citalopram.
Semaglutide Injection	Semaglutide Injection The risk or severity of hypoglycemia can be increased when Citalopram is combined with Semaglutide.
Tetrabenazine	Tetrabenazine The risk or severity of QTc prolongation can be increased when Citalopram is combined with Tetrabenazine.
Ertugliflozin	Ertugliflozin The risk or severity of hypoglycemia can be increased when Citalopram is combined with Ertugliflozin.
Buprenorphine Injection	Buprenorphine Injection Citalopram may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide	Apalutamide The serum concentration of Citalopram can be increased when it is combined with Apalutamide.
Baricitinib	Baricitinib The metabolism of Baricitinib can be decreased when combined with Citalopram.
Lofexidine	Lofexidine The therapeutic efficacy of Citalopram can be increased when used in combination with Lofexidine.
Eliglustat	Eliglustat The metabolism of Eliglustat can be decreased when combined with Citalopram.
Encorafenib	Encorafenib The risk or severity of QTc prolongation can be increased when Citalopram is combined with Encorafenib.
Binimetinib	Binimetinib The metabolism of Binimetinib can be decreased when combined with Citalopram.
Ivosidenib	Ivosidenib The metabolism of Citalopram can be decreased when combined with Ivosidenib.
Elagolix	Elagolix The metabolism of Elagolix can be decreased when combined with Citalopram.
Tafenoquine	Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Citalopram.
Cannabidiol	Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Citalopram.
Dacomitinib	Dacomitinib The metabolism of Citalopram can be decreased when combined with Dacomitinib.
Duvelisib	Duvelisib The metabolism of Duvelisib can be decreased when combined with Citalopram.
Stiripentol	Stiripentol The serum concentration of Citalopram can be increased when it is combined with Stiripentol.
Gilteritinib	Gilteritinib The therapeutic efficacy of Citalopram can be decreased when used in combination with Gilteritinib.
Glasdegib	Glasdegib The risk or severity of QTc prolongation can be increased when Citalopram is combined with Glasdegib.
Lorlatinib	Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Citalopram.
Paclitaxel (with albumin) Injection	Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Citalopram.
Rifamycin	Rifamycin Rifamycin may increase the QTc-prolonging activities of Citalopram.
Prucalopride	Prucalopride The metabolism of Prucalopride can be decreased when combined with Citalopram.
Emapalumab-lzsg Injection	Emapalumab-lzsg Injection The metabolism of Citalopram can be increased when combined with Emapalumab.
Siponimod	Siponimod The metabolism of Siponimod can be decreased when combined with Citalopram.
Acyclovir Ophthalmic	Acyclovir Ophthalmic The metabolism of Acyclovir can be decreased when combined with Citalopram.
Caplacizumab-yhdp Injection	Caplacizumab-yhdp Injection The risk or severity of hemorrhage can be increased when Citalopram is combined with Caplacizumab.
Erdafitinib	Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Citalopram.
Esomeprazole Injection	Esomeprazole Injection The risk or severity of QTc prolongation can be increased when Esomeprazole is combined with Citalopram.
Alpelisib	Alpelisib Alpelisib may increase the QTc-prolonging activities of Citalopram.
Brexanolone Injection	Brexanolone Injection The risk or severity of adverse effects can be increased when Brexanolone is combined with Citalopram.
Solriamfetol	Solriamfetol The risk or severity of adverse effects can be increased when Solriamfetol is combined with Citalopram.
Triclabendazole	Triclabendazole The metabolism of Citalopram can be decreased when combined with Triclabendazole.
Entrectinib	Entrectinib The risk or severity of QTc prolongation can be increased when Citalopram is combined with Entrectinib.
Pexidartinib	Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Citalopram.
Istradefylline	Istradefylline The metabolism of Istradefylline can be decreased when combined with Citalopram.
Pitolisant	Pitolisant The serum concentration of Citalopram can be decreased when it is combined with Pitolisant.
Fedratinib	Fedratinib The metabolism of Fedratinib can be decreased when combined with Citalopram.
Lefamulin	Lefamulin Citalopram may increase the QTc-prolonging activities of Lefamulin.
Phenytoin Injection	Phenytoin Injection The metabolism of Citalopram can be decreased when combined with Phenytoin.
Fosphenytoin Injection	Fosphenytoin Injection The metabolism of Fosphenytoin can be decreased when combined with Citalopram.
Zanubrutinib	Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Citalopram.
Voxelotor	Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Citalopram.
Lumateperone	Lumateperone The risk or severity of adverse effects can be increased when Lumateperone is combined with Citalopram.
Lasmiditan	Lasmiditan The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Citalopram.
Ubrogepant	Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Citalopram.
Tazemetostat	Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Citalopram.
Cenobamate	Cenobamate Citalopram may increase the QTc-prolonging activities of Cenobamate.
Selumetinib	Selumetinib The metabolism of Selumetinib can be decreased when combined with Citalopram.
Tucatinib	Tucatinib The metabolism of Tucatinib can be decreased when combined with Citalopram.
Lemborexant	Lemborexant The risk or severity of adverse effects can be increased when Lemborexant is combined with Citalopram.
Fenfluramine	Fenfluramine The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Fenfluramine.
Fostemsavir	Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Citalopram.
Octreotide	Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Citalopram.
Satralizumab-mwge Injection	Satralizumab-mwge Injection The serum concentration of Citalopram can be decreased when it is combined with Satralizumab.
Relugolix	Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Citalopram.
Progestin-Only (drospirenone) Oral Contraceptives	Progestin-Only (drospirenone) Oral Contraceptives The metabolism of Drospirenone can be decreased when combined with Citalopram.
Viloxazine	Viloxazine The risk or severity of adverse effects can be increased when Citalopram is combined with Viloxazine.
Theophylline	Theophylline The metabolism of Theophylline can be decreased when combined with Citalopram.
Fenoprofen	Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Fenoprofen.
Indomethacin	Indomethacin Indomethacin may increase the QTc-prolonging activities of Citalopram.
Mefenamic Acid	Mefenamic Acid The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Mefenamic acid.
Naproxen	Naproxen The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Citalopram.
Tolmetin	Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Tolmetin.
Sulindac	Sulindac The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Sulindac.
Trazodone	Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Citalopram.
Hydroxyurea	Hydroxyurea The metabolism of Citalopram can be decreased when combined with Hydroxyurea.
Phenobarbital	Phenobarbital The metabolism of Citalopram can be decreased when combined with Phenobarbital.
Metaxalone	Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram.
Methotrexate Injection	Methotrexate Injection The metabolism of Methotrexate can be decreased when combined with Citalopram.
Levorphanol	Levorphanol The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Citalopram.
Primidone	Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Citalopram.
Methsuximide	Methsuximide Methsuximide may increase the QTc-prolonging activities of Citalopram.
Diethylpropion	Diethylpropion The risk or severity of adverse effects can be increased when Citalopram is combined with Diethylpropion.
Chlorpromazine	Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Citalopram.
Diazepam	Diazepam Diazepam may increase the QTc-prolonging activities of Citalopram.
Oxazepam	Oxazepam The risk or severity of adverse effects can be increased when Citalopram is combined with Oxazepam.
Flurazepam	Flurazepam The risk or severity of adverse effects can be increased when Citalopram is combined with Flurazepam.
Clorazepate	Clorazepate The risk or severity of adverse effects can be increased when Citalopram is combined with Clorazepic acid.
Lorazepam	Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Citalopram.
Carmustine	Carmustine The metabolism of Carmustine can be decreased when combined with Citalopram.
Amantadine	Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Citalopram.
Codeine	Codeine The risk or severity of serotonin syndrome can be increased when Codeine is combined with Citalopram.
Meprobamate	Meprobamate The risk or severity of adverse effects can be increased when Citalopram is combined with Meprobamate.
Chlordiazepoxide	Chlordiazepoxide The risk or severity of adverse effects can be increased when Citalopram is combined with Chlordiazepoxide.
Bromocriptine	Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Citalopram.
Tranylcypromine	Tranylcypromine The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Citalopram.
Phenelzine	Phenelzine The risk or severity of serotonin syndrome can be increased when Phenelzine is combined with Citalopram.
Procarbazine	Procarbazine The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Citalopram.
Ergoloid Mesylates	Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Citalopram.
Minocycline	Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Citalopram.
Prochlorperazine	Prochlorperazine The risk or severity of QTc prolongation can be increased when Citalopram is combined with Prochlorperazine.
Thioridazine	Thioridazine The metabolism of Thioridazine can be decreased when combined with Citalopram.
Trifluoperazine	Trifluoperazine The risk or severity of adverse effects can be increased when Citalopram is combined with Trifluoperazine.
Sulfadiazine	Sulfadiazine The risk or severity of hypoglycemia can be increased when Citalopram is combined with Sulfadiazine.
Oxycodone	Oxycodone The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Citalopram.
Methadone	Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Citalopram.
Oxybutynin	Oxybutynin The metabolism of Citalopram can be decreased when combined with Oxybutynin.
Benztropine	Benztropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Citalopram.
Maprotiline	Maprotiline The risk or severity of adverse effects can be increased when Citalopram is combined with Maprotiline.
Ibuprofen	Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ibuprofen.
Trihexyphenidyl	Trihexyphenidyl Citalopram may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine	Orphenadrine Citalopram may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine	Perphenazine The risk or severity of adverse effects can be increased when Citalopram is combined with Perphenazine.
Azathioprine	Azathioprine The metabolism of Azathioprine can be decreased when combined with Citalopram.
Fluphenazine	Fluphenazine The risk or severity of adverse effects can be increased when Citalopram is combined with Fluphenazine.
Phentermine	Phentermine The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Citalopram.
Amoxapine	Amoxapine The metabolism of Citalopram can be decreased when combined with Amoxapine.
Sulfasalazine	Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Sulfasalazine.
Doxorubicin	Doxorubicin The metabolism of Citalopram can be decreased when combined with Doxorubicin.
Carbamazepine	Carbamazepine Carbamazepine may increase the QTc-prolonging activities of Citalopram.
Molindone	Molindone The risk or severity of adverse effects can be increased when Citalopram is combined with Molindone.
Clonidine	Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Citalopram.
Cimetidine	Cimetidine The serum concentration of Citalopram can be increased when it is combined with Cimetidine.
Warfarin	Warfarin Warfarin may increase the QTc-prolonging activities of Citalopram.
Clonazepam	Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Citalopram.
Loperamide	Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Citalopram.
Promethazine	Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Citalopram.
Meclofenamate	Meclofenamate The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Meclofenamic acid.
Digoxin	Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Citalopram.
Loxapine	Loxapine The risk or severity of adverse effects can be increased when Citalopram is combined with Loxapine.
Chloroquine	Chloroquine The metabolism of Citalopram can be decreased when combined with Chloroquine.
Quinine	Quinine Quinine may increase the QTc-prolonging activities of Citalopram.
Ethosuximide	Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Citalopram.
Triamterene	Triamterene The metabolism of Triamterene can be decreased when combined with Citalopram.
Sulfinpyrazone	Sulfinpyrazone The risk or severity of hemorrhage can be increased when Citalopram is combined with Sulfinpyrazone.
Chlorothiazide	Chlorothiazide The risk or severity of hyponatremia can be increased when Citalopram is combined with Chlorothiazide.
Chlorthalidone	Chlorthalidone The risk or severity of hyponatremia can be increased when Citalopram is combined with Chlorthalidone.
Metolazone	Metolazone The risk or severity of hyponatremia can be increased when Citalopram is combined with Metolazone.
Secobarbital	Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram.
Desipramine	Desipramine The metabolism of Citalopram can be decreased when combined with Desipramine.
Amitriptyline	Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Citalopram.
Imipramine	Imipramine Imipramine may increase the QTc-prolonging activities of Citalopram.
Probenecid	Probenecid Probenecid may increase the QTc-prolonging activities of Citalopram.
Quinidine	Quinidine The metabolism of Quinidine can be decreased when combined with Citalopram.
Procainamide	Procainamide The metabolism of Procainamide can be decreased when combined with Citalopram.
Isoniazid	Isoniazid The serum concentration of Citalopram can be increased when it is combined with Isoniazid.
Rifampin	Rifampin The serum concentration of Citalopram can be decreased when it is combined with Rifampicin.
Disopyramide	Disopyramide The risk or severity of QTc prolongation can be increased when Citalopram is combined with Disopyramide.
Valproic Acid	Valproic Acid Valproic acid may increase the QTc-prolonging activities of Citalopram.
Tamoxifen	Tamoxifen The metabolism of Citalopram can be decreased when combined with Tamoxifen.
Butabarbital	Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Citalopram.
Levothyroxine	Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Citalopram.
Liothyronine	Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Citalopram.
Methimazole	Methimazole Methimazole may increase the QTc-prolonging activities of Citalopram.
Propylthiouracil	Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Citalopram.
Chlorpropamide	Chlorpropamide The risk or severity of hypoglycemia can be increased when Citalopram is combined with Chlorpropamide.
Tolbutamide	Tolbutamide The risk or severity of hypoglycemia can be increased when Citalopram is combined with Tolbutamide.
Tolazamide	Tolazamide The risk or severity of hypoglycemia can be increased when Citalopram is combined with Tolazamide.
Dextromethorphan	Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Citalopram.
Cyclobenzaprine	Cyclobenzaprine The risk or severity of CNS depression can be increased when Citalopram is combined with Cyclobenzaprine.
Niacin	Niacin The metabolism of Citalopram can be decreased when combined with Niacin.
Baclofen	Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Citalopram.
Doxylamine	Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Citalopram.
Cyproheptadine	Cyproheptadine The therapeutic efficacy of Citalopram can be decreased when used in combination with Cyproheptadine.
Clemastine	Clemastine The risk or severity of QTc prolongation can be increased when Citalopram is combined with Clemastine.
Chlorpheniramine	Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Citalopram.
Brompheniramine	Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram.
Meclizine	Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Citalopram.
Methyclothiazide	Methyclothiazide The risk or severity of hyponatremia can be increased when Citalopram is combined with Methyclothiazide.
Hydrochlorothiazide	Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Citalopram.
Dantrolene	Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram.
Chlorzoxazone	Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Citalopram.
Carisoprodol	Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Citalopram.
Methocarbamol	Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Citalopram.
Disulfiram	Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Citalopram.
Propranolol (Cardiovascular)	Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Citalopram.
Pseudoephedrine	Pseudoephedrine The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Pseudoephedrine.
Nortriptyline	Nortriptyline The metabolism of Citalopram can be decreased when combined with Nortriptyline.
Nadolol	Nadolol The metabolism of Nadolol can be decreased when combined with Citalopram.
Butorphanol Injection	Butorphanol Injection The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Citalopram.
Nalbuphine Injection	Nalbuphine Injection The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Citalopram.
Oxytocin Injection	Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Citalopram.
Trimethobenzamide	Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Citalopram.
Flavoxate	Flavoxate Citalopram may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine	Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Citalopram.
Fluorouracil Injection	Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Citalopram.
Colchicine	Colchicine The metabolism of Colchicine can be decreased when combined with Citalopram.
Cephalexin	Cephalexin The metabolism of Cephalexin can be decreased when combined with Citalopram.
Dacarbazine	Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Citalopram.
Acetazolamide	Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Citalopram.
Calcitonin Salmon Injection	Calcitonin Salmon Injection The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Citalopram.
Ketoconazole	Ketoconazole Ketoconazole may increase the QTc-prolonging activities of Citalopram.
Pyrantel	Pyrantel The risk or severity of adverse effects can be increased when Pyrantel is combined with Citalopram.
Thiotepa Injection	Thiotepa Injection The metabolism of Thiotepa can be decreased when combined with Citalopram.
Vincristine Injection	Vincristine Injection The metabolism of Vincristine can be decreased when combined with Citalopram.
Dipyridamole	Dipyridamole The risk or severity of hemorrhage can be increased when Citalopram is combined with Dipyridamole.
Vinblastine	Vinblastine The metabolism of Citalopram can be decreased when combined with Vinblastine.
Metoprolol	Metoprolol The metabolism of Metoprolol can be decreased when combined with Citalopram.
Hydroxyzine	Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Citalopram.
Thiothixene	Thiothixene The risk or severity of adverse effects can be increased when Citalopram is combined with Thiothixene.
Aspirin	Aspirin The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Acetylsalicylic acid.
Salsalate	Salsalate The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Salsalate.
Alprazolam	Alprazolam The metabolism of Alprazolam can be decreased when combined with Citalopram.
Temazepam	Temazepam The risk or severity of adverse effects can be increased when Citalopram is combined with Temazepam.
Triazolam	Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Citalopram.
Dicyclomine	Dicyclomine Citalopram may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine	Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Citalopram.
Propantheline	Propantheline Citalopram may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Diltiazem	Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Citalopram.
Nifedipine	Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Citalopram.
Timolol	Timolol The metabolism of Timolol can be decreased when combined with Citalopram.
Verapamil	Verapamil The metabolism of Verapamil can be decreased when combined with Citalopram.
Atenolol	Atenolol The metabolism of Atenolol can be decreased when combined with Citalopram.
Pindolol	Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Citalopram.
Diflunisal	Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Diflunisal.
Piroxicam	Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Piroxicam.
Etoposide	Etoposide The metabolism of Etoposide can be decreased when combined with Citalopram.
Glyburide	Glyburide The metabolism of Glyburide can be decreased when combined with Citalopram.
Glipizide	Glipizide The risk or severity of hypoglycemia can be increased when Citalopram is combined with Glipizide.
Indapamide	Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Citalopram.
Pentoxifylline	Pentoxifylline The risk or severity of hemorrhage can be increased when Citalopram is combined with Pentoxifylline.
Pentamidine Injection	Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Citalopram.
Labetalol	Labetalol The metabolism of Citalopram can be decreased when combined with Labetalol.
Leuprolide Injection	Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Citalopram.
Gemfibrozil	Gemfibrozil The serum concentration of Citalopram can be increased when it is combined with Gemfibrozil.
Guanabenz	Guanabenz The metabolism of Guanabenz can be decreased when combined with Citalopram.
Ketoprofen	Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ketoprofen.
Pimozide	Pimozide The risk or severity of QTc prolongation can be increased when Citalopram is combined with Pimozide.
Flurbiprofen	Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Flurbiprofen.
Amiodarone	Amiodarone The metabolism of Amiodarone can be decreased when combined with Citalopram.
Buspirone	Buspirone The metabolism of Buspirone can be decreased when combined with Citalopram.
Lovastatin	Lovastatin The metabolism of Lovastatin can be decreased when combined with Citalopram.
Ciprofloxacin	Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Citalopram.
Mesalamine	Mesalamine The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Mesalazine.
Diclofenac	Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Citalopram.
Fluoxetine	Fluoxetine The serum concentration of Citalopram can be increased when it is combined with Fluoxetine.
Nimodipine	Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Citalopram.
Clozapine	Clozapine The risk or severity of QTc prolongation can be increased when Clozapine is combined with Citalopram.
Estazolam	Estazolam The risk or severity of adverse effects can be increased when Citalopram is combined with Estazolam.
Idarubicin	Idarubicin The metabolism of Idarubicin can be decreased when combined with Citalopram.
Ofloxacin	Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Citalopram.
Clarithromycin	Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Citalopram.
Etodolac	Etodolac The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Etodolac.
Felodipine	Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Citalopram.
Nabumetone	Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Nabumetone.
Simvastatin	Simvastatin The metabolism of Simvastatin can be decreased when combined with Citalopram.
Teniposide Injection	Teniposide Injection The metabolism of Teniposide can be decreased when combined with Citalopram.
Itraconazole	Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Citalopram.
Oxaprozin	Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Oxaprozin.
Rifabutin	Rifabutin The metabolism of Citalopram can be increased when combined with Rifabutin.
Sotalol	Sotalol The metabolism of Sotalol can be decreased when combined with Citalopram.
Zolpidem	Zolpidem Citalopram may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin	Doxazosin The metabolism of Doxazosin can be decreased when combined with Citalopram.
Isradipine	Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Citalopram.
Omeprazole	Omeprazole The risk or severity of QTc prolongation can be increased when Omeprazole is combined with Citalopram.
Cisapride	Cisapride The metabolism of Citalopram can be decreased when combined with Cisapride.
Gabapentin	Gabapentin The risk or severity of adverse effects can be increased when Citalopram is combined with Gabapentin.
Fluvastatin	Fluvastatin Fluvastatin may increase the QTc-prolonging activities of Citalopram.
Venlafaxine	Venlafaxine The metabolism of Venlafaxine can be decreased when combined with Citalopram.
Famciclovir	Famciclovir The metabolism of Famciclovir can be decreased when combined with Citalopram.
Fluvoxamine	Fluvoxamine The serum concentration of Citalopram can be increased when it is combined with Fluvoxamine.
Nefazodone	Nefazodone The risk or severity of adverse effects can be increased when Citalopram is combined with Nefazodone.
Lamotrigine	Lamotrigine The risk or severity of adverse effects can be increased when Citalopram is combined with Lamotrigine.
Losartan	Losartan Losartan may increase the QTc-prolonging activities of Citalopram.
Tramadol	Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Citalopram.
Vinorelbine Injection	Vinorelbine Injection The metabolism of Citalopram can be decreased when combined with Vinorelbine.
Moexipril	Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Citalopram.
Lansoprazole	Lansoprazole The serum concentration of Citalopram can be increased when it is combined with Lansoprazole.
Ifosfamide Injection	Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Citalopram.
Nicardipine	Nicardipine Nicardipine may increase the QTc-prolonging activities of Citalopram.
Bupropion	Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with Citalopram.
Ticlopidine	Ticlopidine The serum concentration of Citalopram can be increased when it is combined with Ticlopidine.
Saquinavir	Saquinavir The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Citalopram.
Metformin	Metformin The risk or severity of hypoglycemia can be increased when Citalopram is combined with Metformin.
Dalteparin Injection	Dalteparin Injection The risk or severity of hemorrhage can be increased when Citalopram is combined with Dalteparin.
Riluzole	Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Citalopram.
Acarbose	Acarbose The risk or severity of hypoglycemia can be increased when Citalopram is combined with Acarbose.
Glimepiride	Glimepiride The risk or severity of hypoglycemia can be increased when Citalopram is combined with Glimepiride.
Ritonavir	Ritonavir Ritonavir may increase the QTc-prolonging activities of Citalopram.
Docetaxel Injection	Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Citalopram.
Clomipramine	Clomipramine The serum concentration of Citalopram can be increased when it is combined with Clomipramine.
Zafirlukast	Zafirlukast The serum concentration of Citalopram can be increased when it is combined with Zafirlukast.
Mirtazapine	Mirtazapine Citalopram may increase the serotonergic activities of Mirtazapine.
Topiramate	Topiramate Topiramate may increase the QTc-prolonging activities of Citalopram.
Zileuton	Zileuton The metabolism of Zileuton can be decreased when combined with Citalopram.
Insulin Lispro Injection	Insulin Lispro Injection The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Citalopram.
Pramipexole	Pramipexole Citalopram may increase the sedative activities of Pramipexole.
Donepezil	Donepezil The risk or severity of adverse effects can be increased when Citalopram is combined with Donepezil.
Nelfinavir	Nelfinavir The risk or severity of QTc prolongation can be increased when Citalopram is combined with Nelfinavir.
Azithromycin	Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Citalopram.
Carvedilol	Carvedilol The metabolism of Carvedilol can be decreased when combined with Citalopram.
Nilutamide	Nilutamide The risk or severity of QTc prolongation can be increased when Nilutamide is combined with Citalopram.
Flutamide	Flutamide The metabolism of Flutamide can be decreased when combined with Citalopram.
Selegiline	Selegiline The risk or severity of serotonin syndrome can be increased when Selegiline is combined with Citalopram.
Bicalutamide	Bicalutamide Bicalutamide may increase the QTc-prolonging activities of Citalopram.
Sertraline	Sertraline The serum concentration of Citalopram can be increased when it is combined with Sertraline.
Propafenone	Propafenone The metabolism of Citalopram can be decreased when combined with Propafenone.
Letrozole	Letrozole Letrozole may increase the QTc-prolonging activities of Citalopram.
Tamsulosin	Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Citalopram.
Ropinirole	Ropinirole The risk or severity of adverse effects can be increased when Citalopram is combined with Ropinirole.
Quetiapine	Quetiapine The risk or severity of QTc prolongation can be increased when Citalopram is combined with Quetiapine.
Cetirizine	Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Citalopram.
Paroxetine	Paroxetine Citalopram may increase the QTc-prolonging activities of Paroxetine.
Tolcapone	Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Citalopram.
Efavirenz	Efavirenz The serum concentration of Citalopram can be increased when it is combined with Efavirenz.
Sildenafil	Sildenafil The risk or severity of QTc prolongation can be increased when Sildenafil is combined with Citalopram.
Pioglitazone	Pioglitazone The risk or severity of hypoglycemia can be increased when Citalopram is combined with Pioglitazone.
Celecoxib	Celecoxib The risk or severity of bleeding can be increased when Celecoxib is combined with Citalopram.
Rosiglitazone	Rosiglitazone The metabolism of Citalopram can be decreased when combined with Rosiglitazone.
Tolterodine	Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Citalopram.
Thalidomide	Thalidomide Citalopram may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Balsalazide	Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Balsalazide.
Nateglinide	Nateglinide The metabolism of Nateglinide can be decreased when combined with Citalopram.
Galantamine	Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Citalopram.
Levetiracetam	Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Citalopram.
Rabeprazole	Rabeprazole Rabeprazole may increase the QTc-prolonging activities of Citalopram.
Terbinafine	Terbinafine The metabolism of Citalopram can be decreased when combined with Terbinafine.